Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Following the strength, is AMGN a buy right now? Or is the market overestimating its value? Find out in our full research report, it's free for active Edge members Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Amgen's sales grew at a decent 7.6% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. If you've followed StockStory for a while, you know
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC]CNBC
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website